Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM) Meeting Abstract


Authors: Omuro, A. M.; Beal, K.; Karimi, S.; Chan, T. A.; Panageas, K.; Nayak, L.; Seko, B.; DeAngelis, L. M.; Abrey, L. E.; Gutin, P. H.
Abstract Title: Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)
Meeting Title: 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 28
Issue: 15 Suppl.
Meeting Dates: 2010 Jun 4-8
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2010-05-20
Start Page: 188s
Language: English
ACCESSION: WOS:000208852003031
PROVIDER: wos
DOI: 10.1200/jco.2010.28.15_suppl.2036
Notes: Meeting Abstract: 2036 -- S -- Source: Wos
Altmetric Score
MSK Authors
  1. Timothy Chan
    215 Chan
  2. Philip H Gutin
    152 Gutin
  3. Antonio Marcilio Padula Omuro
    176 Omuro
  4. Kathryn Beal
    157 Beal
  5. Sasan Karimi
    97 Karimi
  6. Lakshmi Nayak
    18 Nayak
  7. Lauren E Abrey
    272 Abrey
  8. Katherine S Panageas
    327 Panageas
  9. Brian Stephen Seko
    3 Seko